$0.67
-0.04 (-5.11%)
Open$0.69
Previous Close$0.70
Day High$0.70
Day Low$0.66
52W High$2.35
52W Low$0.36
Volume—
Avg Volume3.14M
Market Cap152.09M
P/E Ratio—
EPS$-0.63
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+5,335.3% upside
Current
$0.67
$0.67
Target
$36.15
$36.15
$26.32
$36.15 avg
$48.95
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 59.14M | 52.95M | 62.98M |
| Net Income | 4.93M | 4.47M | 5.16M |
| Profit Margin | 8.3% | 8.4% | 8.2% |
| EBITDA | 5.59M | 4.86M | 6.72M |
| Free Cash Flow | 3.58M | 3.18M | 3.67M |
| Rev Growth | +23.4% | +5.7% | +6.5% |
| Debt/Equity | 0.46 | 0.42 | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |